The US Federal Trade Commission announced Wednesday that pharmaceutical giant Novartis offered to divest its nicotine patch Habitrol to secure clearance for a joint venture.
Reports say Novartis offered the concessions to reduce competition concerns over its proposed partnership with UK-based GlaxoSmithKline. The agreement would see Novartis acquiring Glaxo’s oncology drugs portfolio, while Glaxo would take on Novartis’s non-flu vaccines operations.
But according to reports, the two conglomerates are among just three companies that sell nicotine patches to US retailers. Reports did not indicate whether the FTC will accept the concessions offered, however.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Italy’s Antitrust Regulator Investigates State Railway Operators for Market Abuse
Mar 23, 2025 by
CPI
Democrats Urge Trump to Reinstate Ousted FTC Commissioners
Mar 23, 2025 by
CPI
White House-Led Talks Focus on U.S. Investor Takeover of TikTok
Mar 23, 2025 by
CPI
Oregon Lawmakers Target Algorithmic Price-Fixing in Rental Market
Mar 23, 2025 by
CPI
New Merger Disclosure Rules Double Review Time, Complicate Deal Process
Mar 23, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li